Discovery Days
We use cookies to customize content and ads, to provide social features, and to analyze traffic on our site. We may also share your usage information with social media platforms and other partners, for advertising and statistical purposes. To manage or disable these cookies, click on "Cookie settings." For more information, please click on our Cookie Policy.
Accept
Decline
You are now leaving the patient meeting registration website.
This external link is provided to you for your convenience.
STAY ON CURRENT PAGE
CONTINUE TO WEBSITE
REGISTER NOW
For US residents only | Full prescribing Information
Learn, Share, and Be Inspired.
REGISTER NOW
Register for an Elfabrio® patient meeting today!
We understand that what matters most is you. Whether you’re an individual affected by rare disease, caregiver, doctor, or business partner, you drive us to build a better world. A world in which everyone can find the treatment and care we need.
Chiesi Global Rare Diseases.
Committed to every single life.
Learn more about Fabry disease
Hear about Elfabrio from a real patient and an expert
Learn how the long-lasting ERT can help you manage your Fabry disease*
Elfabrio Discovery Days
REGISTER NOW
Elfabrio is an enzyme replacement therapy (ERT) that has been shown to work safely and effectively over the long term in adults with Fabry disease.† And with a long half-life,* Elfabrio can last for a long time in your body.
Elfabrio, designed with your needs in mind
GO TO ELFABRIO.COM
† Trials within the Full Prescribing Information extend up to 2 years.
Indication
Elfabrio® (pegunigalsidase alfa-iwxj) is a prescription infusion medicine used to treat adults with confirmed Fabry disease.
Important Safety Information
What should I know about Elfabrio infusions?
Your healthcare provider may give you other medications prior to your Elfabrio infusions to help manage allergic reactions and infusion-related side effects. They will explain how to recognize the signs and symptoms of these allergic reactions and infusion-related side effects. If these signs and symptoms occur, it’s important for you to seek immediate medical care. If the reaction is mild to moderate, your healthcare provider may choose to slow the infusion rate or withhold the dose.
In clinical trials, 41 patients (29%) experienced an infusion-related side effect. The most common signs and symptoms of an infusion-related reaction with Elfabrio were hypersensitivity, nausea, chills, itchy skin, rash, chest pain, dizziness, vomiting, feelings of weakness, pain, sneezing, shortness of breath, nasal congestion, throat irritation, abdominal pain, skin redness, diarrhea, burning sensation, nerve pain, headache, tingling or numbness, shaking movements, agitation, increased body temperature, flushing, slow heart rate, muscle pain, high blood pressure, and low blood pressure.
Your healthcare provider will do blood and urine tests to check your kidney function during treatment with Elfabrio.
The most common side effects of Elfabrio include infusion-related side effects, common cold, headache, diarrhea, fatigue, nausea, back pain, pain in the limbs, and sinus infection.
Please see full Prescribing Information for Elfabrio.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
What is the most important information I should know about Elfabrio?
Severe allergic reactions (hypersensitivity reactions), including anaphylaxis, may occur during and after Elfabrio treatment. If severe allergic reactions or anaphylaxis occurs during treatment, your healthcare provider will immediately stop the infusion and provide appropriate medical care. If these reactions should occur after treatment, seek immediate medical care.
Indication
Elfabrio® (pegunigalsidase alfa-iwxj) is a prescription infusion medicine used to treat adults with confirmed Fabry disease.
Important Safety Information
What is the most important information I should know about Elfabrio?
Severe allergic reactions (hypersensitivity reactions), including anaphylaxis, may occur during and after Elfabrio treatment. If severe allergic reactions or anaphylaxis occurs during treatment, your healthcare provider will immediately stop the infusion and provide appropriate medical care. If these reactions should occur after treatment, seek immediate medical care.
What should I know about Elfabrio infusions?
Your healthcare provider may give you other medications prior to your Elfabrio infusions to help manage allergic reactions and infusion-related side effects. They will explain how to recognize the signs and symptoms of these allergic reactions and infusion-related side effects. If these signs and symptoms occur, it’s important for you to seek immediate medical care. If the reaction is mild to moderate, your healthcare provider may choose to slow the infusion rate or withhold the dose.
In clinical trials, 41 patients (29%) experienced an infusion-related side effect. The most common signs and symptoms of an infusion-related reaction with Elfabrio were hypersensitivity, nausea, chills, itchy skin, rash, chest pain, dizziness, vomiting, feelings of weakness, pain, sneezing, shortness of breath, nasal congestion, throat irritation, abdominal pain, skin redness, diarrhea, burning sensation, nerve pain, headache, tingling or numbness, shaking movements, agitation, increased body temperature, flushing, slow heart rate, muscle pain, high blood pressure, and low blood pressure.
Your healthcare provider will do blood and urine tests to check your kidney function during treatment with Elfabrio.
The most common side effects of Elfabrio include infusion-related side effects, common cold, headache, diarrhea, fatigue, nausea, back pain, pain in the limbs, and sinus infection.
Please see full Prescribing Information for Elfabrio.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
+
+
Indication
Elfabrio® (pegunigalsidase alfa-iwxj) is a prescription infusion medicine used to treat adults with confirmed Fabry disease.
Important Safety Information
What is the most important information I should know about Elfabrio?
Severe allergic reactions (hypersensitivity reactions), including anaphylaxis, may occur during and after Elfabrio treatment. If severe allergic reactions or anaphylaxis occurs during treatment, your healthcare provider will immediately stop the infusion and provide appropriate medical care. If these reactions should occur after treatment, seek immediate medical care.
What should I know about Elfabrio infusions?
Your healthcare provider may give you other medications prior to your Elfabrio infusions to help manage allergic reactions and infusion-related side effects. They will explain how to recognize the signs and symptoms of these allergic reactions and infusion-related side effects. If these signs and symptoms occur, it’s important for you to seek immediate medical care. If the reaction is mild to moderate, your healthcare provider may choose to slow the infusion rate or withhold the dose.
In clinical trials, 41 patients (29%) experienced an infusion-related side effect. The most common signs and symptoms of an infusion-related reaction with Elfabrio were hypersensitivity, nausea, chills, itchy skin, rash, chest pain, dizziness, vomiting, feelings of weakness, pain, sneezing, shortness of breath, nasal congestion, throat irritation, abdominal pain, skin redness, diarrhea, burning sensation, nerve pain, headache, tingling or numbness, shaking movements, agitation, increased body temperature, flushing, slow heart rate, muscle pain, high blood pressure, and low blood pressure.
Your healthcare provider will do blood and urine tests to check your kidney function during treatment with Elfabrio.
The most common side effects of Elfabrio include infusion-related side effects, common cold, headache, diarrhea, fatigue, nausea, back pain, pain in the limbs, and sinus infection.
Indication
Elfabrio® (pegunigalsidase alfa-iwxj) is a prescription infusion medicine used to treat adults with confirmed Fabry disease.
Please see full Prescribing Information for Elfabrio.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Privacy Policy | Terms of Use
©Chiesi USA, Inc. 2025. All rights reserved. Privacy Settings. Elfabrio® is a registered trademark owned by Chiesi Farmaceutici. PP-RA-00679 V1.0
You are now leaving the patient meeting registration website.
This external link is provided to you for your convenience.
STAY ON CURRENT PAGE
CONTINUE TO WEBSITE
You are now leaving the patient meeting registration website.
This external link is provided to you for your convenience.
STAY ON CURRENT PAGE
CONTINUE TO WEBSITE
Important Safety Information
What is the most important information I should know about Elfabrio?
Severe allergic reactions (hypersensitivity reactions), including anaphylaxis, may occur during and after Elfabrio treatment. If severe allergic reactions or anaphylaxis occurs during treatment, your healthcare provider will immediately stop the infusion and provide appropriate medical care. If these reactions should occur after treatment, seek immediate medical care.
What should I know about Elfabrio infusions?
Your healthcare provider may give you other medications prior to your Elfabrio infusions to help manage allergic reactions and infusion-related side effects. They will explain how to recognize the signs and symptoms of these allergic reactions and infusion-related side effects. If these signs and symptoms occur, it’s important for you to seek immediate medical care. If the reaction is mild to moderate, your healthcare provider may choose to slow the infusion rate or withhold the dose.
In clinical trials, 41 patients (29%) experienced an infusion-related side effect. The most common signs and symptoms of an infusion-related reaction with Elfabrio were hypersensitivity, nausea, chills, itchy skin, rash, chest pain, dizziness, vomiting, feelings of weakness, pain, sneezing, shortness of breath, nasal congestion, throat irritation, abdominal pain, skin redness, diarrhea, burning sensation, nerve pain, headache, tingling or numbness, shaking movements, agitation, increased body temperature, flushing, slow heart rate, muscle pain, high blood pressure, and low blood pressure.
Your healthcare provider will do blood and urine tests to check your kidney function during treatment with Elfabrio.
The most common side effects of Elfabrio include infusion-related side effects, common cold, headache, diarrhea, fatigue, nausea, back pain, pain in the limbs, and sinus infection.
Please see full Prescribing Information for Elfabrio.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
+
Elfabrio Discovery Days meetings are intended for an adult audience.
Jeff, living with Fabry disease.
Molly, living with Fabry disease.
*Trials within the Full Prescribing Information extend up to 2 years.
† Elfabrio has an initial half-life of 78.9 ± 10.3 hours. Clinical studies have not shown that a long half-life results in a medicine working better or more safely. Infusions are every 2 weeks.
Not an actual patient. Patient symptoms will vary. Your doctor will determine the best course of therapy.
Register for an Elfabrio® patient meeting today!
REGISTER NOW
*Trials within the Full Prescribing Information extend up to 2 years.
† Elfabrio has an initial half-life of 78.9 ± 10.3 hours. Clinical studies have not shown that a long half-life results in a medicine working better or more safely. Infusions are every 2 weeks.
*Elfabrio has an initial half-life of 78.9 ± 10.3 hours. Clinical studies have not shown that a long half-life results in a medicine working better or more safely. Infusions are every 2 weeks.